You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY20 is not expected to be complete until September, 2021.

  1. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: N

    DESCRIPTION provided by applicant The aim of this innovative proposal is to commercialize a non invasive topical product that treats uveitis which is safe and easy to administer Uveitis is the third leading cause of blindness in the United States Heretofore the primary treatment of intermediate and posterior uveitis has been either oral medications with significant systemic side effects or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. Anti-Inflammatory Glycosaminoglycan Ethers for Treatment of Periodontitis

    SBC: GLYCOMIRA, LLC            Topic: NIDCR

    DESCRIPTION provided by applicant Chronic gingival inflammation of the soft tissue surrounding the tooth afflicts over half of all American adults In the most severely affected progression of this inflammatory process to the deeper periodontal ligaments and alveolar bone results in tooth loss from loss of mandibular anchorage Gingivitis and periodontitis are initiated by chronic infection o ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  3. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION provided by applicant Development of radiological nuclear medical countermeasures to treat Acute Radiation Syndrome ARS is a high priority research area for NIAID Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure often resulting i death Granulocyte colony stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  4. Therapeutic D-peptide Inhibitor of HIV Entry

    SBC: NAVIGEN, INC.            Topic: NIAID

    DESCRIPTION provided by applicant With million people living with HIV AIDS including million in the US and million AIDS related deaths annually HIV AIDS remains a formidable global epidemic UNAIDS CDC Modern HIV therapy combines drugs from different classes to form andquot cocktailandquot therapies that have significantly prolonged the lives of many HIV patients However side effects and drug resis ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Long-Acting G-CSF Analog for Treating ARS

    SBC: BOLDER BIOTECHNOLOGY INC            Topic: NIAID

    DESCRIPTION (provided by applicant): Development of radiological/nuclear medical countermeasures to treat Acute Radiation Syndrome (ARS) is a high priority research area for NIAID. Bone marrow is one of the most sensitive tissues to radiation damage and impaired hematopoiesis is one of the first clinical signs of excessive radiation exposure, often resulting i death. Granulocyte colony-stimulating ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Point-of-Care HIV Antigen/Antibody Diagnostic Device

    SBC: Mbio Diagnostics, Inc.            Topic: NIAID

    DESCRIPTION (provided by applicant): MBio Diagnostics, Inc. proposes to develop a low-cost, point-of-care (POC), HIV-1/2 antigen/antibody combination diagnostic device. The goal is for the Ag/Ab combo system to deliver the performance of laboratory based,4th generation antigen/antibody clinical analyzers, in a POC platform with cost and workflow of the widely used HIV rapid tests. Phase I research ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  7. Non-Invasive Treatment for Uveitis

    SBC: ACIONT, INC.            Topic: NEI

    DESCRIPTION (provided by applicant): The aim of this innovative proposal is to commercialize a non-invasive topical product that treats uveitis which is safe and easy to administer. Uveitis is the third leading cause of blindness in the United States. Heretofore, the primary treatment of intermediate and posterior uveitis has been either oral medications (with significant systemic side effects) or ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Mesodissection Device Phase II

    SBC: AVANSCI BIO, LLC            Topic: NIGMS

    DESCRIPTION (provided by applicant): Microscopic analysis of tissue mounted on glass slides is commonly used to study cancer, non-neoplastic entities such as heart disease and diabetes, and normal cell function. Researchers utilize micro and macro tissue dissection techniques in order to recover specific areas of these tissue sections from the slides for subsequent molecular analysis including rea ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Fetal Magnetocardiography Using Non-cryogenic Magnetic Field Sensors

    SBC: QUSPIN INC.            Topic: NICHD

    DESCRIPTION (provided by applicant): While the number of diagnostic technologies available for adult applications continues to grow, there remains a paucity of technologies suitable for fetal evaluation. In particular, noninvasive assessment of fetal cardiac electrophysiology has not been routinely possible despite many decades of fetal ECG research. Recently, a number of groups have demonstrated ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  10. Micro_patterned Surfaces for Reducing the Risk of Ventilator_Associated Pneumonia

    SBC: Sharklet Technologies Inc.            Topic: NHLBI

    DESCRIPTION (provided by applicant): Ventilator-associated pneumonia (VAP) is the most costly and second most common hospital-acquired infection (HAI), accounting for over 86% of hospital-acquired pneumonia (HAP). Some 300,000 HAP patients are treated annually in the U.S., at an estimated annual hospital cost of more than 1.5 billion. The current paradigm for preventing VAP has been to implement ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government